Comparative Pharmacology
Head-to-head clinical analysis: AMBRISENTAN versus TRACLEER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMBRISENTAN versus TRACLEER.
AMBRISENTAN vs TRACLEER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Endothelin receptor antagonist (ERA) that selectively binds to endothelin type A (ETA) receptors in pulmonary vascular smooth muscle, blocking endothelin-1-mediated vasoconstriction and proliferation.
Bosentan is a dual endothelin receptor antagonist (ERA) that blocks endothelin-1 (ET-1) from binding to ETA and ETB receptors in pulmonary vascular smooth muscle and endothelium, reducing vasoconstriction and cell proliferation.
10 mg orally once daily, with or without food, for patients not receiving cyclosporine. For patients receiving cyclosporine, reduce dose to 5 mg once daily.
Initial: 62.5 mg twice daily orally for 4 weeks, then increase to maintenance: 125 mg twice daily orally.
None Documented
None Documented
Clinical Note
moderateAmbrisentan + Teriflunomide
"The serum concentration of Teriflunomide can be increased when it is combined with Ambrisentan."
Clinical Note
moderateAmbrisentan + Methylphenidate
"Ambrisentan may decrease the antihypertensive activities of Methylphenidate."
Clinical Note
moderateAmbrisentan + Sulfisoxazole
"The metabolism of Sulfisoxazole can be decreased when combined with Ambrisentan."
Clinical Note
moderateAmbrisentan + Erythromycin
Terminal elimination half-life is approximately 9 hours (range 4–20 hours) in healthy subjects; no significant accumulation is observed with once-daily dosing.
Terminal elimination half-life is approximately 4-5 hours in healthy adults. In patients with pulmonary arterial hypertension, half-life may be slightly prolonged (up to 6-8 hours) due to reduced clearance.
Primarily via nonrenal pathways, with fecal excretion accounting for approximately 77% of a radiolabeled dose (as unchanged drug and metabolites) and renal excretion for about 22% (mostly as metabolites).
Primarily hepatic metabolism (CYP2C9 and CYP3A4) with biliary excretion of unchanged drug and metabolites. Renal excretion of unchanged drug is negligible (<1%). Fecal excretion accounts for ~75% of total clearance, with ~25% excreted in urine as metabolites.
Category C
Category C
Endothelin Receptor Antagonist
Endothelin Receptor Antagonist
"The metabolism of Erythromycin can be decreased when combined with Ambrisentan."